Quarterly report pursuant to Section 13 or 15(d)

Revenues - Additional Information (Detail)

v3.2.0.727
Revenues - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
May. 31, 2011
Sep. 30, 2010
Aug. 31, 2009
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2012
Dec. 31, 2011
Feb. 28, 2013
Deferred Revenue Arrangement [Line Items]                    
Revenues from product sales           $ 0        
Collaborative Arrangement [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments         $ 400,000 0 $ 400,000      
Allergan Inc [Member] | Collaborative Arrangement [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments           0        
Allergan Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments       $ 13,000,000   13,000,000        
Allergan Inc [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, license revenue     $ 10,000,000              
Sanofi [Member] | Collaborative Arrangement [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments       0 0 0 300,000      
Collaboration agreement, revenue recognized       0 200,000 $ 0 700,000      
Description of factors in determining milestones substantive           Factors considered in determining the options were substantive were whether (i) Sanofi could obtain the overall objective of the agreement without exercising any options, (ii) Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii) the cost to exercise the options was significant relative to the total upfront payment of $4.9 million for two licenses and four options, and (iv) exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi.        
Collaborative arrangement, consideration   $ 8,100,000                
Sanofi [Member] | Collaborative Arrangement [Member] | Expired Option Agreement [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, revenue recognized                 $ 700,000  
Sanofi [Member] | Collaborative Arrangement [Member] | Options Exercised [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, revenue recognized               $ 350,000    
Collaborative arrangement, consideration                   $ 280,000
Sanofi [Member] | Collaborative Arrangement [Member] | Options, Exercised Price [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaborative arrangement, consideration                   $ 1,100,000
Sanofi [Member] | Collaborative Arrangement [Member] | Licenses [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaborative arrangement, consideration   3,500,000                
Sanofi [Member] | Collaborative Arrangement [Member] | Options to Acquire Additional Licenses [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaborative arrangement, consideration   1,400,000                
Sanofi [Member] | Collaborative Arrangement [Member] | Research Services [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Research collaboration agreement, estimated period               2 years    
Collaborative arrangement, consideration   3,200,000                
Sanofi [Member] | Collaborative Arrangement [Member] | Research Services [Member] | Extension Term [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Research collaboration agreement, estimated period               40 months    
Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments   51,600,000                
Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Research Milestones [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments   1,900,000                
Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments   29,600,000                
Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Commercial Milestones [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments   20,100,000                
Sanofi [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, license revenue   $ 4,900,000                
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Research collaboration agreement, estimated period           2 years        
Collaboration agreement, revenue recognized       $ 0 $ 400,000 $ 0 $ 1,100,000      
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments $ 91,100,000                  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Research Milestones [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments 2,600,000                  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments 37,400,000                  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Commercial Milestones [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments 50,200,000                  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Additional Diagnostic Milestones [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, milestone payments 900,000                  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]                    
Deferred Revenue Arrangement [Line Items]                    
Collaboration agreement, license revenue $ 10,100,000